Angiomax® (bivalirudin)
for injection

Product Overview

Angiomax® (bivalirudin) is an anticoagulant currently approved in the US and other countries for use in patients undergoing coronary angioplasty procedures. Angiomax works by directly inhibiting thrombin, a key factor involved in the formation of blood clots, to help prevent clot formation during angioplasty.

The Medicines Company believes Angiomax will become the leading replacement for heparin in acute cardiovascular care. Heparin, an indirect thrombin inhibitor, was discovered almost 100 years ago and is a commonly used anticoagulant to treat arterial thrombosis. Angiomax has the potential to become a broadly applied intravenous anticoagulant in the treatment of arterial thrombosis.

Safety Considerations

ANGIOMAX with provisional use of glycoprotein IIb/IIIa inhibitor is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), and in patients with or at risk for heparin-induced thrombocytopenia and thrombosis syndrome (HIT/HITTS) undergoing PCI. ANGIOMAX is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin. ANGIOMAX is contraindicated in patients with active major bleeding or hypersensitivity to ANGIOMAX or its components. The most common (10%) adverse events for ANGIOMAX were back pain, pain, nausea, headache, and hypotension. An unexplained fall in blood pressure or hematocrit, or any unexplained symptom, should lead to serious consideration of a hemorrhagic event and cessation of ANGIOMAX administration. Please see complete prescribing information.